TNGX - Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual Meeting | Benzinga
– Data support the ongoing clinical development of TNG908 and TNG462 PRMT5 inhibitors for the treatment of MTAP-deleted cancers –
BOSTON, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that two abstracts have been selected for poster presentations at the Society for Neuro-Oncology (SNO) 28th Annual Meeting taking place November 15-19, 2023, in Vancouver, Canada.
"As we advance TNG908 and TNG462, our two MTA-cooperative PRMT5 inhibitors, in phase 1/2 clinical trials, we are pleased to share preclinical data at SNO that affirm their potential as new therapies for patients with MTAP-deleted cancers, including glioblastoma and malignant peripheral nerve sheath tumors," said Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics. "TNG908 demonstrates strong antitumor activity in MTAP-deleted glioblastoma models. Additionally, data from preclinical malignant peripheral nerve sheath tumor models evaluating TNG908 and TNG462 demonstrate efficacy at well-tolerated doses. TNG462 is potentially best-in-class. Dose escalation of TNG908 and TNG462 in phase 1/2 trials is ongoing."
Abstracts accepted for poster presentation
Title: TNG908, a brain-penetrant MTA-cooperative PRMT5 inhibitor, is efficacious in preclinical MTAP-deleted models including glioblastoma
Poster #: DDDR-33
Presenter: Minjie Zhang, Ph.D., Associate Director, Pharmacology, Tango Therapeutics
Date and Time: Friday, November 17, 2023; 7:30 – 9:30 p.m. PT
- Glioblastoma (GBM), the most common malignant primary brain tumor in adults, has a poor prognosis and represents a significant unmet need for more effective therapies. TNG908, a clinical stage MTA-cooperative PRMT5 inhibitor for the treatment of MTAP-deleted solid tumors, is shown to be brain penetrant and drives strong antitumor activity in preclinical models of MTAP-deleted GBM.
Title: MTA-cooperative PRMT5 inhibitors are efficacious in MTAP-deleted malignant peripheral nerve sheath tumor models
Poster #: EXTH-63
Presenter: Xiaochun Zhang, M.D., Staff Scientist, Hirbe Lab, Washington University School of Medicine in St. Louis
Date and Time: Friday, November 17, 2023; 7:30 – 9:30 p.m. PT
- Malignant peripheral nerve sheath tumors (MPNSTs) are highly aggressive sarcomas with limited treatment options and poor survival rates. The clinical stage MTA-cooperative PRMT5 inhibitors TNG908 and TNG462 are efficacious in MPNST preclinical models and represent potential new therapeutic strategies for patients with MTAP-deleted MPNST.
Abstract titles, presentation information and text are currently available to the public in the 2023 abstract supplement to SNO's official journal, Neuro-Oncology.
About Tango Therapeutics
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. ...